Fierce Biotech April 18, 2024
Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines.
“It’s an almost limitless market opportunity,” Metsera CEO Clive Meanwell, M.D., told Fierce Biotech in an interview. The leader is a British oncologist with an extensive industry track record that includes founding and leading The Medicines Company, a biotech that homed cardiovascular medicine inclisiran (Leqvio) and was acquired by Novartis in 2019 for $9.7 billion. “I think we have a real shot here of making some major products.”
Meanwell also helped form and is a partner of private equity firm Population Health Partners. The firm, alongside Arch Venture Partners, launched Metsera during biotech’s...
Today's Sponsors
Today's Sponsor